Mission Pharmacal announced that the Food and Drug Administration (FDA) has approved its Abbreviated New Drug Application (ANDA) for over-the-counter (OTC) liquid Potassium Iodide Oral Solution for use in the event of a nuclear emergency.
Potassium Iodide is a thyroid blocking agent that can be used by all ages. Potassium Iodide is already available as tablets but the oral solution is recommended for infants and small children as it provides accurate and precise dosing. It works by saturating the thyroid with nonradioactive iodine and preventing the uptake of the radioactive molecules. It further reduces the risk of thyroid cancer in individuals at risk for inhalation or ingestion of radioactive iodine.
Mission Pharmacal plans to start manufacturing Potassium Iodide Oral Solution immediately.
For more information call (210) 696-8400 or visit liquidKI.com.